|
|
|
|
|
| Ellison, J. A.; Johnson, S. R.; Kuzmina, N. K.; Gilbert, A. T.; Carson, W. C.; Blanton, J. D.; VerCauteren, K.; Rupprecht, C.. |
| Zoonotic disease surveillance is typically initiated after an animal pathogen has caused disease in humans. Early detection of potentially high-risk pathogens within animal hosts may facilitate medical interventions to cope with an emerging disease. To effectively spillover to a novel host, a pathogen may undergo genetic changes resulting in varying transmission potential in the new host and potentially to humans. Rabies virus (RABV) is one model pathogen to consider for studying the dynamics of emerging infectious diseases under both laboratory and field conditions. The evolutionary history of RABV is characterized by regularly documented spillover infections and a series of notable host-shifts. Within this context, enhanced field surveillance to improve... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/3164 |
| |
|
|
| Smith, T. G.; Ellison, J. A.; Carson, W. C.; Ma, X.; Rupprecht, C.. |
| Vaccine potency testing is necessary to evaluate the immunogenicity of inactivated rabies virus (RABV) vaccine preparations before human or veterinary application. Currently, the NIH test is recommended by the WHO expert committee to evaluate intra- and inter-lot variation of RABV vaccines; however, numerous disadvantages are inherent concerning cost, number of animals and biosafety requirements. As such, numerous in vitro methods (e.g. antigen-capture ELISA) have been proposed for the evaluation of vaccines based on RABV glycoprotein (G) quality and quantity which correlates with vaccine potency. In this study an antigen-capture electrochemiluminescent (ECL) assay was developed utilizing three murine anti-RABV G monoclonal antibodies (mAb) to quantify... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/3154 |
| |
|
|
|
